In this second of a three-part video series, Craig Samitt, CEO and president of Blue Cross Blue Shield of Minnesota talks with MHE about healthcare utilization, MLR rates and investing in telehealth models for the better care of its members.
Medical Loss Ratio (MLR) rates for Blue Cross Blue Shield of Minnesota are closely relatable to where the utilization rates were at this time last year, according to Craig Samitt, CEO and president of the organization.
BCBS of Minnesota is currently experiencing a "double peak" in healthcare use, which means they are seeing COVID-19 case frequency and hospitalization rates in the state at the highest it's been since the pandemic began, Samitt says.
Related: Healthcare Use at 'Double Peak' Through BCBS Minnesota
Due to this double peak, Samitt says their MLR rates were the lowest at the beginning of the pandemic because they've had a significant rise in healthcare utilization.
"We want to end the year on budget, as was originally designed because the investments, the favorability that we've experienced, either has gone into premium relief, it's gone into racial and health inequities or social determinants of health, or other investments that we can make to avoid an even worsening, sick community or to to help resolve the the inequities that we've seen in the industry," he says. "(Additionally), it's investing in sort of better telehealth infrastructure or better care delivery infrastructure so that next year, premiums don't rise."
In relation to telehealth, Samitt says BCBS of Minnesota is investing in models they believe are going to be more contemporary in primary care delivery.
"So we had shared before that we've gotten into the care delivery business, I think I had talked about being like Netflix, where we get into content, you very much are doing that because we see a hunger by patients and by consumers in an alternative care delivery model that isn't facility centric," he says. "And whether that's telehealth or mobile, urgent care, or care coordination, and the home, those are the things that we're investing in, because we believe that they're going to ultimately create a higher value model for patients that we're hungry for. I think we want our industry as high performing as other industries."
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Conversations with Perry and Friends: Saar Mahna, J.D., MBA
July 7th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.
Listen
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
Conversations With Perry and Friends: Paul Fronstin, Ph.D.
May 9th 2025Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.
Listen
FDA Accepts Tabelecleucel BLA; Priority Review Granted for Post-Transplant Disease Therapy
July 24th 2025The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).
Read More